SCHEMBL10004642

SCHEMBL10004642

CCOC(=O)c1c(OCC(F)(F)F)c2c(=O)n(CC(=O)c3ccccc3)c(OCC)nc2n1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMO Q99835 1/20 0.44
▸ DPP4 P27487 3/20 0.42
▸ KMT2A Q03164 4/20 0.41
▸ MEN1 O00255 3/20 0.41
▸ ALDH1A1 P00352 4/20 0.40
▸ POLB P06746 2/20 0.40
▸ GAA P10253 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ CYP1A2 P05177 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ LMNA P02545 1/20 0.36
▸ NPSR1 Q6W5P4 2/20 0.36
▸ RXFP1 Q9HBX9 1/20 0.35
▸ BLM P54132 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ ADORA3 P0DMS8 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10004335 0.88 SMO (0.43) SMODPP4KMT2AMEN1ALDH1A1
SCHEMBL10004699 0.87 SMO (0.44) SMODPP4KMT2AMEN1ALDH1A1
SCHEMBL10004065 0.81 KMT2A (0.43) KMT2AMEN1ALDH1A1POLBGAA
SCHEMBL1061866 0.81 SMO (0.54) SMOKMT2AMEN1ALDH1A1POLB
SCHEMBL10003928 0.81 SMO (0.71) SMODPP4KMT2ACYP2D6CYP2C19
SCHEMBL10003752 0.80 MAPT (0.47) KMT2AMEN1ALDH1A1POLBGAA
SCHEMBL1061982 0.80 SMO (0.65) SMOKMT2AMEN1ALDH1A1POLB
SCHEMBL10004300 0.77 TDP1 (0.50) KMT2AMEN1ALDH1A1POLBGAA
SCHEMBL10004316 0.76 KDM4E (0.52) KMT2AMEN1ALDH1A1POLBGAA
SCHEMBL10004501 0.76 ALDH1A1 (0.43) KMT2AMEN1ALDH1A1POLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471793-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2016-10-05 — — EP disclosed
US-8614208-B2 Fused heterocyclic ring derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-12-24 — — US disclosed
US-20120214795-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-23 — — US disclosed
EP-2471793-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214795-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH SMO 1/4885DPP4 996/4885KMT2A 423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback